Finanzen von Sangamo Therapeutics Inc (SGMO)SGMOSangamo Therapeutics Inc

Evaluating the bottom line, Sangamo Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2215.40%, while the net margin is -2149.45%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SGMO converts its operational activities into shareholder value.

In the context of the broader market, SGMO competes directly with industry leaders such as HYFT and INKT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SGMO's gross margin of 100.00% stands against HYFT's 60.63% and INKT's N/A. Such benchmarking helps identify whether Sangamo Therapeutics Inc is trading at a premium or discount relative to its financial performance.

In Q4 2025, revenue increased by 88.43% YoY to $14.23M. Net income improved by 59.94% YoY but remains negative at -$37.42M. EPS remains flat at -0.11. Gross margin is stable at 100%.